Journal
MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA
Volume 16, Issue 4, Pages 551-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.mric.2008.07.011
Keywords
Gadolinium-based contrast agents; Late adverse reactions; Nephrogenic systemic fibrosis
Ask authors/readers for more resources
Gadolinium-based contrast agents were for many years considered safe, but this is no longer the case. The least stable agents may trigger the development of nephrogenic systemic fibrosis (NSF), a generalized fibrotic disorder, in renal failure patients. The use of gadodiamide and gadopentetate dimeglumine is now contraindicated in Europe and Japan in patients who have a glomerular filtration rate less than 30 mL/min/1.73 m(2), including those on dialysis. The fear of NSF, however, should not lead to an enhanced MR imaging examination being denied when there is a good clinical indication to give a gadolinium-based contrast agent.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available